A practical reference on WADA prohibited list: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-10 and is reviewed periodically as new material appears.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
He also invited Xi and his wife, Peng Liyuan, to visit the White House on 24 September 2026. The table arrangement and menu of the state banquet that night were circulated online afterward. Compared to Trump's last visit to China, the main table sits fewer people. The foods featured both Chinese culinary traditions and American elements. It included cold hors d'oeuvre dishes, main dishes such as golden lobster soup, crispy beef, Peking duck, salmon with mustard sauce, bean soup with fresh vegetables, and after mains including pan-fried buns with ice flowers, conch pastry, tiramisu, fruit, ice cream, coffee, tea, as well as Great Wall Chief Winemaker's Selected Cabernet Sauvignon 2009 from Hebei, China, and Changyu Reserve Chardonnay 2016 from Beijing, China. It was also rumored that the People's Liberation Army Military Band played 6 Chinese songs and 6 American songs during the state banquet. The Chinese songs included "Butterfly Lovers" and "Ru Yuan" sung by Faye Wong, while the last song played was Trump's campaign song "Y.M.C.A."
=== General === Peter Atkins & Julio de Paula, 2006, "Physical chemistry," 8th Edn., New York, NY, USA:Macmillan, ISBN 0716787598, accessed 21 June 2015. [E.g., see p. 422 for a group theoretical/symmetry description of atomic orbitals contributing to bonding in methane, CH4, and pp. 390f for estimation of π-electron binding energy for 1,3-butadiene by the Hückel method.] Thomas H. Lowry & Kathleen Schueller Richardson, 1987, Mechanism and Theory in Organic Chemistry, 3rd Edn., New York, NY, USA:Harper & Row, ISBN 0060440848, accessed 20 June 2015. [The authoritative textbook on the subject, containing a number of appendices that provide technical details on molecular orbital theory, kinetic isotope effects, transition state theory, and radical chemistry.] Eric V. Anslyn & Dennis A. Dougherty, 2006, Modern Physical Organic Chemistry, Sausalito, Calif.: University Science Books, ISBN 1891389319. [A modernized and streamlined treatment with an emphasis on applications and cross-disciplinary connections.] Michael B. Smith & Jerry March, 2007, "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure," 6th Ed., New York, NY, USA:Wiley & Sons, ISBN 0470084944, accessed 19 June 2015. Francis A. Carey & Richard J. Sundberg, 2006, "Advanced Organic Chemistry: Part A: Structure and Mechanisms," 4th Edn., New York, NY, USA:Springer Science & Business Media, ISBN 0306468565, accessed 19 June 2015. Hammett, Louis P. (1940) Physical Organic Chemistry, New York, NY, USA: McGraw Hill, accessed 20 June 2015.
== General bibliography == Duane, H. D. Roller; Thilorier, M. (1952). "Thilyorier and the First Solidification of a "Permanent" Gas (1835)". Isis. 43 (2): 109–113. doi:10.1086/349402. JSTOR 227174. S2CID 144091865. Goroll, Allan H; Mulley, Albert G (2009). Primary Care Medicine: Office evaluation and management of the adult patient. Lippincott Williams & Wilkins. ISBN 978-0-7817-7513-7. Häring, Heinz-Wolfgang (2008). Industrial Gases Processing. Christine Ahner. Wiley-VCH. ISBN 978-3-527-31685-4. Retrieved 2009-07-31. Housecroft, Catherine; Sharpe, Alan G (2001). Inorganic chemistry. Harlow: Prentice Hall. p. 410. ISBN 978-0-582-31080-3. Retrieved 2009-07-31. Keyes, Conrad G (2006). Guidelines for Cloud Seeding to Augment Precipitation. American Society of Civil Engineers. ASCE Publications. ISBN 978-0-7844-0819-3. Verma, N. K.; Khanna, S. K.; Kapila, B. (2008). Comprehensive Chemistry for Class XI. New Delhi: Laxmi Publications. ISBN 978-81-7008-596-6. Retrieved 2009-07-31. McCarthy, Robert E. (1992). Secrets of Hollywood Special Effects. Boston: Focal Press. ISBN 978-0-240-80108-7. Mitra, Somenath (April 2004). Sample Preparation Techniques in Analytical Chemistry. Wiley-IEEE. ISBN 978-0-471-32845-2. Retrieved 2009-07-31. Treloar, Roy D. (2003). Plumbing Encyclopaedia (3rd ed.). Wiley-Blackwell. p. 175. ISBN 978-1-4051-0613-9. Retrieved 2009-07-31. Yaws, Carl (2001). Matheson Gas Data Book (7th ed.). McGraw-Hill Professional. ISBN 978-0-07-135854-5. 982 pages. Retrieved 2009-07-27.
In recent years, the use of freeze-dried starter culture has become common due to stability of the fermentation result, because the species of microbes are selected in laboratory conditions, as well as easy transportation. During fermentation, changes in the composition of ingredients occur. Lactose, the sugar present in milk, is broken down mostly to lactic acid by the lactic acid bacteria, which results in acidification. Propionibacteria further break down some of the lactic acid into propionic acid (these bacteria also carry out the same fermentation in Swiss cheese). Other substances that contribute to the flavor of kefir are pyruvic acid, acetic acid, diacetyl and acetoin (both of which contribute a "buttery" flavor), citric acid, acetaldehyde, and amino acids resulting from protein breakdown.
The Australian Wagyu Association is the largest breed association outside Japan. Both fullblood and Wagyu-cross cattle are farmed in Australia for domestic and overseas markets, including China, Denmark, France, Germany, Hong Kong, Indonesia, Singapore, Taiwan, the United Kingdom and the United States. Australian Wagyu cattle are grain fed for the last 300–500 days of production. Wagyu bred in Western Australia's Margaret River region often have red wine added to their feed as well.
Sources: en.wikipedia.org
=== Deficiency === Diminished secretion of LH can result in failure of gonadal function (hypogonadism). This condition is typically manifest in males as failure in production of normal numbers of sperm. In females, amenorrhea is commonly observed. Conditions with very low LH secretions include:
However there have not been any in vivo or in vitro studies of magnetic nanoparticles being used to deliver drugs to the arteries to effectively reduce inflammation. Other potential applications of magnetic nanoparticles are brain imaging and drug delivery past the blood-brain barrier (BBB) using biodegradable magnetic iron oxide nanoparticles. The scope of this application is the treatment of central nervous system (CNS) disorders by functioning as contrast agents and drug carriers. To cross the BBB, these nanoparticles are designed by creating specificity to the BBB; this is achieved by designing the surface of the nanoparticles to be engrafted to ligands, antibodies, small molecules, cell-penetrating peptides, or conjugated RNA to target specific receptors situated along the BBB in order to facilitate entry. As opposed to methods of drug delivery that result in drugs being removed from the cerebrospinal fluid (CSF) or being degraded, magnetic nanoparticle delivery presents an opportunity to protect therapeutics as well as encourage more efficient delivery following the introduction of the nanoparticles. Magnetic nanoparticles can also be used in conjunction with imaging modalities like ultrasound to improve imaging. The use of nanoparticles in ophthalmic drug delivery is also being explored in clinical research. Magnetic nanoparticles inserted into rats' corneas or administered in an eye drop solution showed high adhesion to the target site. However, the exact mechanism by which the adhesion occurred is still being researched.
An example is the trp gene in bacteria. When there is a high level of tryptophan in the region, it is inefficient for the bacterium to synthesize more. When the RNA polymerase binds and transcribes the trp gene, the ribosome will start translating. (This differs from eukaryotic cells, where RNA must exit the nucleus before translation starts.) The attenuator sequence, which is located between the mRNA leader sequence (5' UTR) and trp operon gene sequence, contains four domains, where domain 3 can pair with domain 2 or domain 4. The attenuator sequence at domain 1 contains instruction for peptide synthesis that requires tryptophans. A high level of tryptophan will permit ribosomes to translate the attenuator sequence domains 1 and 2, allowing domains 3 and 4 to form a hairpin structure, which results in termination of transcription of the trp operon. Since the protein coding genes are not transcribed due to rho independent termination, no tryptophan is synthesised. In contrast, a low level of tryptophan means that the ribosome will stall at domain 1, causing the domains 2 and 3 to form a different hairpin loop structure that does not signal termination of transcription. Therefore, the rest of the operon will be transcribed and translated, so that tryptophan can be produced. Thus, domain 4 is an attenuator. Without domain 4, translation can continue regardless of the level of tryptophan. The attenuator sequence has its codons translated into a leader peptide, but is not part of the trp operon gene sequence.
== Research == Noribogaine was first described in the scientific literature by at least 1958. It was first identified and described as a metabolite of ibogaine by 1995. The first evaluation of noribogaine in humans was published in 2015. In April 2026, the FDA allowed a Phase I clinical study of noribogaine hydrochloride to proceed in the United States.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.